Information Provided By:
Fly News Breaks for October 14, 2016
BLUE
Oct 14, 2016 | 07:42 EDT
Leerink analyst Michael Schmidt raised his price target for bluebird bio to $80 from $67 as he sees the clinical development and regulatory path for the company's pipeline products incrementally more de-risked. While development of key product LentiGlobin in transfusion-dependent beta-thalassemia and severe sickle cell disease has been more complex than initially anticipated, the analyst believes bluebird bio is well positioned to overcome remaining technical hurdles. He reiterates an Outperform rating on the shares.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.